<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467452</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA1-07</org_study_id>
    <secondary_id>2014-001487-35</secondary_id>
    <nct_id>NCT02467452</nct_id>
  </id_info>
  <brief_title>Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI) Versus Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®) for the Treatment of Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the triple combination of beclometasone&#xD;
      dipropionate + formoterol fumarate + glycopyrronium bromide is effective in term of quality&#xD;
      of life in COPD patients (Chronic Obstructive Pulmonary Disease).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score at Week 26.</measure>
    <time_frame>26 weeks</time_frame>
    <description>the primary efficacy variable is the numeric value of the change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SGRQ response (change from baseline in total score ≤ -4) at Week 26.</measure>
    <time_frame>26 weeks</time_frame>
    <description>the secondary efficacy variable is derived as a categorisation of this value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rced expiratory volume at one second (FEV1) response (change from baseline in pre-dose morning FEV1 ≥ 100 ml) at Week 26.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1479</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>BDP/FF/GB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FlF/VI + Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/FF/GB</intervention_name>
    <arm_group_label>BDP/FF/GB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FlF/VI + Tiotropium</intervention_name>
    <arm_group_label>FlF/VI + Tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female adults aged ≥ 40 years with written informed consent obtained prior to&#xD;
             any study-related procedure.&#xD;
&#xD;
          2. Patients with a diagnosis of COPD at least 12 months before the screening visit&#xD;
             (according to GOLD document updated 2014).&#xD;
&#xD;
          3. Current smokers or ex-smokers who quit smoking at least 6 months prior to screening&#xD;
             visit, with a smoking history of at least 10 pack years [pack-years = (number of&#xD;
             cigarettes per day x number of years)/20].&#xD;
&#xD;
          4. A post-bronchodilator FEV1 &lt; 50% of the predicted normal value and a&#xD;
             post-bronchodilator forced expiratory volume at one second (FEV1)/forced vital&#xD;
             capacity (FVC) &lt; 0.7 at least 10-15 min after 4 puffs (4 x 100 μg) of salbutamol pMDI.&#xD;
             If this criterion is not met at screening, the test can be repeated once before&#xD;
             randomisation.&#xD;
&#xD;
          5. A documented history of at least one exacerbation in the 12 months preceding the&#xD;
             screening visit.&#xD;
&#xD;
             COPD exacerbation will be defined according to the following:&#xD;
&#xD;
             &quot;A sustained worsening of the patient's condition (dyspnoea, cough and/or sputum&#xD;
             production/purulence), from the stable state and beyond normal day-to-day variations,&#xD;
             that is acute in onset and necessitates a change in regular medication in a patient&#xD;
             with underlying COPD that includes prescriptions of systemic corticosteroids and/or&#xD;
             antibiotics or need for hospitalization&quot;. Also documented visits to an emergency&#xD;
             department due to COPD exacerbation are considered acceptable to fulfil this&#xD;
             criterion.&#xD;
&#xD;
          6. Patients under double therapy for at least 2 months prior to screening visit with&#xD;
             either:&#xD;
&#xD;
               1. inhaled corticosteroids/long-acting β2-agonist combination (fixed or free),&#xD;
                  without regular use of short-acting muscarinic antagonist (regular use means 2&#xD;
                  puffs 4 times per day at least) or&#xD;
&#xD;
               2. inhaled corticosteroids/long-acting muscarinic antagonist free combination,&#xD;
                  without regular use of short-acting β2-agonist (regular use means 2 puffs 4 times&#xD;
                  per day at least) or&#xD;
&#xD;
               3. Inhaled long-acting β2-agonist and inhaled long-acting muscarinic antagonist or&#xD;
&#xD;
               4. Patients under monotherapy with long-acting muscarinic antagonist for at least 2&#xD;
                  months prior to screening.&#xD;
&#xD;
          7. Symptomatic patients at screening with a CAT score ≥10.&#xD;
&#xD;
          8. A cooperative attitude and ability to use correctly the inhalers.&#xD;
&#xD;
          9. A cooperative attitude and ability to use correctly the daily electronic Diary&#xD;
             (eDiary).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women and all women physiologically capable of becoming pregnant&#xD;
             (i.e. women of childbearing potential) UNLESS are willing to use one or more methods&#xD;
             of contraception as defined in the protocol&#xD;
&#xD;
          2. Patients with a current clinical diagnosis of asthma with a physician-judged need for&#xD;
             inhaled or oral corticosteroid therapy&#xD;
&#xD;
          3. Patients requiring use of the following medications:&#xD;
&#xD;
               1. A course of systemic steroids longer than 3 days for COPD exacerbation in the 4&#xD;
                  weeks prior to screening&#xD;
&#xD;
               2. A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks&#xD;
                  prior to screening&#xD;
&#xD;
               3. phosphodiesterase-4 (PDE4) inhibitors in the 4 weeks prior to screening&#xD;
&#xD;
               4. Use of antibiotics for a lower respiratory tract infection (e.g pneumonia) in the&#xD;
                  4 weeks prior to screening&#xD;
&#xD;
          4. COPD exacerbation requiring prescriptions of systemic corticosteroids and/or&#xD;
             antibiotics or hospitalization during the run-in period&#xD;
&#xD;
          5. Patients treated with non-cardio selective β-blockers in the month preceding the&#xD;
             screening visit or during the run-in period. Those patients may enter the study after&#xD;
             non-selective β-blockers withdrawal and/or cardio selective β-blockers intake for at&#xD;
             least 10 days before randomization&#xD;
&#xD;
          6. Patients treated with long-acting antihistamines unless taken at stable regimen at&#xD;
             least 2 months prior to screening and to be maintained constant during the study, or&#xD;
             if taken as o re nata (PRN).&#xD;
&#xD;
          7. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic&#xD;
             hypoxemia.&#xD;
&#xD;
          8. Known respiratory disorders other than COPD which may impact the efficacy of the study&#xD;
             drug according the investigator's judgment&#xD;
&#xD;
          9. Patients who have clinically significant cardiovascular condition&#xD;
&#xD;
         10. Patients with atrial fibrillation (AF):&#xD;
&#xD;
               1. Paroxysmal Atrial Fibrillation&#xD;
&#xD;
               2. Persistent: AF episode either lasts longer than 7 days or requires termination by&#xD;
                  cardioversion, either with drugs or by direct current cardioversion (DCC) within&#xD;
                  6 months from screening&#xD;
&#xD;
               3. Long standing Persistent as defined by continuous atrial fibrillation diagnosed&#xD;
                  for less than 6 months with or without a rhythm control strategy&#xD;
&#xD;
               4. Permanent: for at least 6 months with a resting ventricular rate ≥ 100/min&#xD;
                  controlled with a rate control strategy (i.e., selective β-blocker, calcium&#xD;
                  channel blocker, pacemaker placement, digoxin or ablation therapy)&#xD;
&#xD;
         11. An abnormal and clinically significant 12-lead ECG which may impact the safety of the&#xD;
             patient according to investigator's judgement Patients whose electrocardiogram (ECG12&#xD;
             lead) shows QT Interval Corrected by the Fridericia Correction Formula (QTcF) &gt;450 ms&#xD;
             for males or QTcF &gt;470 ms for females at screening visit are not eligible (not&#xD;
             applicable for patient with pacemaker)&#xD;
&#xD;
         12. Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck&#xD;
             obstruction that in the opinion of the investigator would prevent use of&#xD;
             anticholinergic agents&#xD;
&#xD;
         13. History of hypersensitivity to anticholinergics, β2-agonist, corticosteroids or any of&#xD;
             the excipients contained in any of the formulations used in the trial which may raise&#xD;
             contra-indications or impact the efficacy of the study drug according to the&#xD;
             investigator's judgement&#xD;
&#xD;
         14. Clinically significant laboratory abnormalities indicating a significant or unstable&#xD;
             concomitant disease which may impact the efficacy or the safety of the study drug&#xD;
             according to investigator's judgement&#xD;
&#xD;
         15. Patients with hypokalaemia (serum potassium levels &lt;3.5 milliequivalent per liter&#xD;
             (mEq/L) (or 3.5 mmol/L)) or uncontrolled hyperkalaemia according to investigator's&#xD;
             judgment&#xD;
&#xD;
         16. Unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes&#xD;
             mellitus or other endocrine disease; significant hepatic impairment; significant renal&#xD;
             impairment; uncontrolled gastrointestinal disease (e.g. active peptic ulcer);&#xD;
             uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled&#xD;
             autoimmune disorders, or other which may impact the efficacy or the safety of the&#xD;
             study drug according to investigator's judgment.&#xD;
&#xD;
         17. Patients with any history of malignancy likely to result in significant disability or&#xD;
             likely to require significant medical or surgical intervention within the next six&#xD;
             months (after V1) or with malignancy for which they are currently undergoing radiation&#xD;
             therapy or chemotherapy&#xD;
&#xD;
         18. History of alcohol abuse and/or substance/drug abuse within 12 months prior to&#xD;
             screening visit&#xD;
&#xD;
         19. Participation in another clinical trial where investigation drug was received less&#xD;
             than 8 weeks prior to screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erzsebet Gondozohaz</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001487-35/results</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <link>
    <url>https://www.chiesi.com/clinic/15_CSR_Synopsis_CCD-05993AA1-07.pdf</url>
    <description>CSR Synopsis available in the CHIESI Clinical Study Register</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.&#xD;
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_description>
    <ipd_access_criteria>Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_access_criteria>
    <ipd_url>https://www.chiesi.com/en/chiesi-clinical-trial-data-request-portal/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

